OTCQB: TNGN , Tengion, Inc. , is a venture stage, regenerative medicine company focused on discovering, developing, manufacturing and commercializing a range of neo-organs.
TNGN is looking exciting with a handful of regenerative medicine products undergoing investigational research.
According to the Company's website, a clinical trial of TNGN 's "Neo-Urinary Conduit" is ongoing in patients with bladder cancer.
Let's get started below on this exciting new profile!
TNGN is looking exciting with a handful of regenerative medicine products undergoing investigational research.
According to the Company's website, a clinical trial of TNGN 's "Neo-Urinary Conduit" is ongoing in patients with bladder cancer.
Let's get started below on this exciting new profile!
Welcome to TNGN
TENGION, Inc.
TENGION, Inc.
: TNGN
The Venture Marketplace
"Beginning in 2014, OTC Markets Group is making changes to make OTCQB a better venture marketplace for entrepreneurial and development stage U.S. and international companies. Companies will be required to meet eligibility standards aimed at improving the information available to investors. To be eligible, U.S. and international companies must be current in their reporting, meet a minimum bid test of $0.01, and undergo a new annual verification and management certification process."
TENGION, INC. - OUR MISSION / REGENERATIVE MEDICINE
As quoted...
"Tengion is a clinical-stage regenerative medicine company discovering and developing regenerative products. Tengion is focusing its resources on large patient populations where the standard of care involves significant costs and potentially complicated procedures with comorbidities that result in reduced quality of life and increased mortality."
"Using its Organ Regeneration Platform™, Tengion is pioneering the development of products comprised of a patient's own (autologous) regenerative cells, with or without a biocompatible material component, that are implanted into the body to engraft into, repair, or replace a damaged tissue or organ. The Company's product candidates harness the body's intrinsic ability to regenerate a range of native-like organs and tissues and are designed to eliminate the need for chronic disease therapies, organ transplantation, and the administration of anti-rejection medications. Tengion's product candidates are designed to replace less effective therapies or become the standard of care treatment in diseases with no current therapy."
“Our Organ Regeneration Platform involves testing different combinations of cell types and biomaterials. We believe this approach enables us to identify accurately the mixture of various cell types and biomaterials for a specific organ necessary to elicit a regenerative response. We own or license 38 U.S. patents and patent applications and over 150 international patents and filings related to our Organ Regeneration Platform and product candidates. ”
THE POTENTIAL - CREATING HUMAN TISSUES
As quoted...
"Tengion's technology has the potential to create new human tissues and organs (neo-tissues and neo-organs) by using the patient's own (autologous) cells. By contrast, organ transplantation from other donors (allogenic transplants) can be associated with rejection and the adverse effects of immunosuppression."
"Tengion's patented technology integrates multiple breakthroughs in tissue engineering and regenerative medicine. While it has long been held that the body contains cells with regenerative power, Tengion is the first company to be able to identify these cells and harness them to create a specific neo-organ, with the potential to create a variety of neo-organs and tissues on a commercial scale. These cells, which come from the patient, are genetically committed to becoming a specific cell type (e.g., a bladder cell), but they are not yet fully differentiated."
"Tengion's organ regeneration process begins when a surgeon sends the patient's biopsy to Tengion. Tengion's scientists identify and multiply the patient's own healthy progenitor cells, and then place these cells on a structure that is shaped like the needed organ or tissue (a bioabsorbable scaffold). The resulting neo-organ becomes ready for implantation after a period of maturation. The surgeon then implants the neo-organ in the patient's body, where it is designed to integrate with the rest of the body and become functional. By contrast, the current therapy for urinary bladder reconstruction requires the surgeon to harvest gastrointestinal tissue from the patient. The harvest and use of gastrointestinal tissue in the urinary tract is associated with acute and chronic risks and complications."
PARTNERSHIPS
As quoted...
"Tengion aggressively explores collaborative relationships and partnership opportunities with academic and industrial partners seeking to bring advanced cell-based regenerative technologies to the market. There are many potential benefits associated with partnering with Tengion:"- Leader in regenerative medicine and tissue engineering with ongoing clinical trials.
- Expert scientific team.
- Unique technical resources with proven competencies in complex, cell-based bioprocesses.
- Integrated team of manufacturing, development, and commercial experts who have previously taken multiple products from IND to successful market launch.
Current Partners
"Tengion's partners include Harvard's Children's Hospital, Wake Forest Institute of Regenerative Medicine, Mario Negri Institute and the collaborating clinical institutions participating in our clinical trials. Tengion has historically partnered with various industrial organizations such as Johnson & Johnson, Medtronic, and currently with Celgene and DaVita to participate in the discovery and early stage development of medicinal products from its technology platform.""Tengion scientists have leading roles with trade organizations and industrial committees with the Alliance for Regenerative Medicine, International Society of Cell Therapies, Tissue Engineering and Regenerative Medical International Society, and the International Society of Stem Cell Research. These partnerships ensure we maximize the advancement of regenerative medical technology and Tengion's pipeline."
IN THE NEWS
News Disclaimer:
Press Release(s) have not been investigated by DITRstocks, therefore, we have no idea if the content of the news release is based on Fact or Fiction. Although the link for the following press release may be from a familiar and reputable news source, you should NOT assume that a press wire hosted by a website you are familiar with is accurate just because it is on their site. DITRstocks will not be held responsible for any news release, including and not limited to misleading or non-factual content, or the accuracy of the identity of the given source of the press release. You should know that press releases found to be questionable can result in a trading halt, by the SEC of the securities in question. Said halt can result in a total loss of investment. The news release has been provided by the company via the OTC Disclosure and News Service. Issuers of news releases and. are solely responsible for the accuracy of such news releases.
- September 22, 2014: Tengion Retains Jefferies to Explore Strategic Options for the Company
- August 13, 2014: Tengion Provides Clinical Update and Reports Second Quarter 2014 Financial Results
- May 15, 2014: Tengion Reports First Quarter 2014 Financial Results
- March 26, 2014: Tengion Reports Fourth Quarter and Full Year 2013 Financial Results
- March 04, 2014: Tengion to Present at the 26th Annual ROTH Conference
- January 13, 2014: Tengion Announces Continued Clinical Progress in Its Two Lead Programs
No comments:
Post a Comment